Federico
Martinón Torres

2024

1. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

   Journal of Infectious Diseases, Vol. 229, pp. S112-S119

2. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

3. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

   Journal of Infectious Diseases, Vol. 229, pp. S100-S111

4. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

5. COVID-19 InfoVaccines: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

6. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

7. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study

   The Lancet Infectious Diseases

8. Erratum to «Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper» [Arch Bronconeumol. 2024;60(3):161–170] (Archivos de Bronconeumología (2024) 60(3) (161–170), (S0300289624000061), (10.1016/j.arbres.2024.01.004))

   Archivos de Bronconeumologia

9. External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care

   The Journal of infectious diseases, Vol. 229, Núm. 1, pp. S18-S24

10. External validation of a multivariable prediction model for identification of pneumonia and other serious bacterial infections in febrile immunocompromised children

    Archives of Disease in Childhood, Vol. 109, Núm. 1, pp. 58-66

11. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

12. Host gene expression signatures to identify infection type and organ dysfunction in children evaluated for sepsis: a multicentre cohort study

    The Lancet Child and Adolescent Health, Vol. 8, Núm. 5, pp. 325-338

13. Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023

    Nature Medicine

14. Multi-tissue transcriptomics of a unique monozygotic discordant twin case of severe progressive osseous heteroplasia

    Genes and Diseases, Vol. 11, Núm. 3

15. Mycoplasma pneumoniae at the rise not only in China: rapid increase of Mycoplasma pneumoniae cases also in Spain

    Emerging Microbes and Infections

16. New Vaccines for Chronic Respiratory Patients

    Archivos de Bronconeumologia

17. Plasma Protein Biomarkers Distinguish Multisystem Inflammatory Syndrome in Children From Other Pediatric Infectious and Inflammatory Diseases

    The Pediatric infectious disease journal, Vol. 43, Núm. 5, pp. 444-453

18. Raising AWaRe-ness of Antimicrobial Stewardship Challenges in Pediatric Emergency Care: Results from the PERFORM Study Assessing Consistency and Appropriateness of Antibiotic Prescribing Across Europe

    Clinical Infectious Diseases, Vol. 78, Núm. 3, pp. 526-534

19. Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 161-170

20. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. 95-107